News

Article

UnitedHealthcare updates Glaucoma Surgical Treatments policy

Key Takeaways

  • UnitedHealthcare's updated policy includes goniotomy, trabeculotomy, and canaloplasty for treating open-angle glaucoma and cataracts, effective October 1, 2025.
  • Sight Sciences' OMNI Surgical System is now part of UHC's expanded coverage, offering minimally invasive glaucoma surgery options.
SHOW MORE

This update from UHC includes procedures enabled with its OMNI Surgical System technology from Sight Sciences.

(Image Credit: AdobeStock/gguy)

(Image Credit: AdobeStock/gguy)

UnitedHealthcare (UHC) has updated its Glaucoma Surgical Treatments policy to include goniotomy, trabeculotomy, canaloplasty (ab interno), combined canaloplasty (ab interno), and trabeculotomy procedures when deemed medically necessary for treating mild to moderate open-angle glaucoma (OAG) and cataracts in adults currently being treated with ocular hypotensive medication.

According to a press release from Sight Sciences, this update from UHC includes procedures enabled with its OMNI Surgical System technology.

The updated coverage policy takes effect on October 1, 2025, and applies to UHC’s commercial and individual exchange benefit plans. UHC currently covers around 50 million Americans.1

Paul Badawi, co-founder and CEO of Sight Sciences, commented on the policy update in a press release from the company, saying, “We are pleased that UHC’s clinical review resulted in expanded coverage for implant-free, minimally invasive glaucoma surgery (MIGS) procedures, including OMNI, which is an important part of the glaucoma treatment paradigm. As a result of this positive coverage policy, UHC’s members will have access to the OMNI technology when deemed medically necessary by their ophthalmologist.”

The OMNI Surgical System is FDA-cleared and indicated for canaloplasty followed by trabeculotomy to reduce intraocular pressure (IOP) in adult patients with primary open-angle glaucoma. The procedure can be performed before, in combination with, or after cataract surgery.

The OMNI Surgical System (Sight Sciences) uses a handpiece to thread a catheter into the Schlemm canal, injecting viscoelastic as it is withdrawn. A newer iteration is the OMNI Edge. The primary advantages of this device are its ease of use and minimal complications. Its limitations are that it only allows movement in 1 direction, 180° at a time, and does not produce the helpful blanching of the episcleral veins.2

References:
  1. Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical Treatments. Published September 9, 2025. Accessed September 9, 2025. https://investors.sightsciences.com/news-releases/news-release-details/sight-sciences-announces-omnir-surgical-system-be-included
  2. Charters L. Glaucoma techniques advance with innovative viscoelastic delivery. Published August 28, 2025. Accessed September 9, 2025. https://www.ophthalmologytimes.com/view/glaucoma-techniques-advance-with-innovative-viscoelastic-delivery

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) EyeCon 2025: Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
© 2025 MJH Life Sciences

All rights reserved.